Adenovirus-based cancer gene therapy

Current Gene Therapy

Volumn 5, Issue 6, 2005, Pages 595-605

  Kaplan, Johanne M ^a  

^a GENZYME CORPORATION   (United States)

Author keywords

Dendritic cells; Immunotherapy; Oncolysis; Suicide gene; Tumor; Vaccine; Vector; Xenograft

Indexed keywords

5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; ADENOVIRUS VECTOR; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BETA GLUCURONIDASE; BREAST CANCER RESISTANCE PROTEIN; CARBOXYLESTERASE; CYCLOPHOSPHAMIDE; CYTOCHROME P450; CYTOSINE DEAMINASE; DOXORUBICIN DERIVATIVE; E1A PROTEIN; EARLY GROWTH RESPONSE FACTOR 1; FLUCYTOSINE; GANCICLOVIR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERFERON; IRINOTECAN; NITROREDUCTASE; ONCOLYTIC VIRUS; ONYX 015; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PRODRUG; PROTEIN KINASE R; PROTEIN P16; PROTEIN P53; RETINOBLASTOMA PROTEIN; THYMIDINE KINASE; TUMOR NECROSIS FACTOR ALPHA; TUMOR SUPPRESSOR PROTEIN; TUMOR VACCINE; UNINDEXED DRUG;

CANCER IMMUNOTHERAPY; CLINICAL TRIAL; DRUG MECHANISM; GENETIC TRANSDUCTION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; NONHUMAN; REVIEW; SUICIDE GENE; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE; TUMOR VASCULARIZATION; VIRAL GENE THERAPY;

ADENOVIRUSES, HUMAN; ANIMALS; COMBINED MODALITY THERAPY; GENE THERAPY; GENETIC VECTORS; HUMANS; IMMUNOTHERAPY; MODELS, BIOLOGICAL; NEOPLASMS;

ADENOVIRIDAE;

EID: 29444445832     PISSN: 15665232     EISSN: None     Source Type: Journal    
DOI: 10.2174/156652305774964677     Document Type: Review

References (116)

1. Afanasieva, T.A., Wittner, M., Vitaliti, A., Ajmo, M., Neri, D., and Klemenz, R. (2003) Single-chain antibody and its derivatives directed against vascular endothelial growth factor: application for antiangiogenic gene therapy. Gene Ther., 10: 1850-1859.
2. Aghi, M., Hochberg, F., and Breakefield, X.O. (2000). Prodrug activation enzymes in cancer gene therapy. J. Gene Med., 2: 148-164.
3. Ali, S., Curtin, J.F., Zirger, J.M., Xiong, W., King, G.D., Barcia, C., Liu, C., Puntel, M., Goverdhana, S., Lowenstein, P.R., and Castro, M.G. (2004) Inflammatory and anti-glioma effects of an adenovirus expressing human soluble Fms-like tyrosine kinase 3 ligand (hsFlt3L): treatment with hsFlt3L inhibits intracranial glioma progression. Mol. Ther., 10: 1071-1084.
4. Balague, C., Noya, F., Alemany, R., Chow, L.T., and Curiel, D.T. (2001) Human papilloma virus E6E7-mediated adenovirus cell killing: selectivity of mutant adenovirus replication in organotypic cultures of human keratinocytes. J. Virol., 75: 7602-7611.
5. Bangari, D.S. and Mittal, S.K. (2004) Porcine adenoviral vectors evade preexisting humoral immunity to adenoviruses and efficiently infect both human and murine cells in culture. Virus Res, 105: 127-136.
6. Barnett, B.G., Crews, C.J., and Douglas, J.T. (2002) Targeted adenoviral vectors. Biochim. Biophys. Acta, 1575: 1-14.
7. Bergelson, J.M., Cunningham, J.A., Droguett, G., Kurt-Jones, E.A., Krithivas, A., Hong, J.S., Horwitz, M.S., Crowell, R.L., and Finberg, R.W. (1997) Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5. Science, 275: 1320-1323.
8. Bischoff, J., Kim, D., Williams, A., Heise, C., Horn, S., Muna, M., Ng, L., Nye, J.A., Sampson-Johannes, A., Fattaey, A, and McCormick, F. (1996) An adenovirus mutant that replicates selectively in p53 deficient human tumor cells. Science, 274: 373-376.
9. Calmels, B., Paul, S., Futin, N., Ledoux, C., Stoecket, F., and Acres, B. (2005) Bypassing tumor-associated immune suppression with recombinant adenovirus constructs expressing membrane bound or secreted GITR-L. Cancer Gene Ther., 12: 198-205.
10. Casado, E., Gomez-Navarro, J., Yamamoto, M., Adachi, Y., Coolidge, C., Arafat, W., Barker, S.D., Wang, M.H., Mahasreshti, P.J., Hemminki, A., Gonzalez-Baron, M., Barnes, M.N., Pustilnik, T.B., Siegal, G.P., Alvarez, R.D., and Curiel, D.T. (2001) Strategies to accomplish targeted expression of transgenes in ovarian cancer for molecular therapeutic applications. Clin. Cancer Res., 7: 2496-2504.
11. Cascallo, M., Capella, G., Mazo, A., and Alemany, R. (2003) Ras-dependent oncolysis with an adenovirus VAI mutant. Cancer Res., 63: 5544-5550.
12. Chen, Y., Emtage, P., Zhu, Q., Foley, R., Muller, W., Hitt, M., Gauldie, J., and Wan, Y. (2001) Induction of ErB-2/neu-specific protective and therapeutic antitumor immunity using genetically modified dendritic cells: enhanced efficacy by cotransduction of gene encoding IL-12. Gene Ther., 8: 316-323.
13. Cho, W.K., Seong, Y.R., Lee, Y.H., Kim, M.J., Hwang, K.S., Yoo, J., Choi, S., Jung, C.R., and Im, D.S. (2004) Oncolytic effects of adenovirus mutant capable of replicating in hypoxic and normoxic regions of solid tumor. Mol. Ther., 10: 938-949.
14. Chu, R.L., Post, D.E., Khuri, F.R., and Van Meir, E.G. (2004) Use of replicating oncolytic adenoviruses in combination therapy for cancer. Clin. Cancer Res., 10: 5299-5312.
15. Ciafre, S.A., Niola, F., Wannenes, F., and Farace, M.G. (2004) An anti-VEGF ribozyme embedded within the adenoviral VAI sequence inhibits glioblastoma cell angiogenic potential in vitro. J. Vasc. Res., 41: 220-228.
16. Curiel, D.T. (1999) Strategies to adapt adenoviral vectors for targeted delivery. Ann. NY. Acad. Sci., 886: 158-171.
17. Dachs, G.U., Tupper, J., and Tozer, G.M. (2005) From bench to bedside for gene-directed enzyme prodrug therapy of cancer. Anticancer Drugs, 16: 349-359.
18. Dmitriev, I., Krasnykh, V., Miller, C.R., Wang, M., Kashentseva, E., Mikheva, G., Belousova, N., and Curiel, D.T. (1998). An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J. Virol., 72: 9706-9713.
19. Dummer, R., Hassel, J.C., Fellenberg, F., Eichmuller, S., Maier, T., Slos, P., Acres, B., Bleuzen, P., Bataille, V., Suiban, P., Burg, G., and Urosevic, M. (2004) Adenovirus-mediated intralesional interferon-gamma gene transfer induces tumor regressions in cutaneous lymphomas. Blood, 104: 1631-1638.
20. Ebbinghaus, C., Al-Jaibaji, A., Operschall, E., Schoffel, A., Peter, I., Greber, U.F., and Hemmi, S. (2001) Functional and selective targeting of adenovirus to high-affinity Fc gamma receptor I-positive cells by using a bispecific hybrid adapter. J. Virol., 75: 480-489.
21. Flint, J., and Shenk, T. (1997) Viral transactivating proteins. Annu. Rev. Genet., 31: 177-212.
22. Folkman, J. (1990) What is the evidence that tumors are angiogenesis dependent? J. Natl. Cancer Inst., 82: 4-6.
23. Fueyo, J., Gomez-Manzano, C., Alemany, R., Lee, P., McDonnel, T., Mittlianga, P., Shi, Y.X., Levin, V.A., Yung, W.K., and Kyritsis, A.P. (1999) A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. OncoGene, 19: 1-11.
24. Fueyo, J., Alemany, R., Gomez-Manzano, C., Fuller, G.N., Khan, A., Conrad, C.A., Liu, T.J., Jiang, H., Lemoine, M.G., Suzuki, S.K., Sawaya, R., Curiel, D.T., Yung, W.K., and Lang, F.F. (2003) Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. J. Natl. Cancer Inst., 95: 652-660.
25. Fukuda, K., Abei, M., Ugai, H., Seo, E., Wakayama, M., Murata, T., Todoroti, T., Tanaka, N., Hamada, H., and Yokoyama, K.K. (2003) E1A, E1B double-restricted adenovirus for oncolytic gene therapy of gall-bladder cancer. Cancer Res., 63: 4434-4440.
26. Fulci, G., Ishii, N., and Van Meir, E.G. (1998) p53 and brain tumors: from gene mutations to gene therapy. Brain Pathol., 8: 599-613.
27. Fushimi, T., Kojima, A., Moore, M.A., and Crystal, R.G. (2000) Macrophage inflammatory protein 3 alpha transgene attracts dendritic cells to established murine tumors and suppresses tumor growth. J. Clin. Invest., 105: 1383-1393.
28. Gambotto, A., Tuting, T., McVey, D.L., Kovesdi, I., Tahara, H., Lotze, M.T., and Robbins, P. (1999) Induction of antitumor immunity by direct intratumoral injection of a recombinant adenovirus vector expressing interleukin-12. Cancer Gene Ther., 6: 45-53.
29. Gao, J.Q., Tsuda, Y., Katayama, K., Nakayama, T., Hatanaka, Y., Tani, Y., Mizuguchi, H., Hayakawa, T., Yoshie, O., Tsutsumi, Y., Mayumi, T., and Nakagawa, S. (2003) Antitumor effect by interleukin-11 receptor alpha-locus chemokine/CCL27, introduced into tumor cells through a recombinant adenovirus vector. Cancer Res., 63: 4420-4425.
30. Gao, J.Q., Sugita, T., Kanagawa, N., Iida, K., Eto, Y., Motomura, Y., Mizuguchi, H., Tsutsumi, Y., Hayakawa, T., Mayumi, T., and Nakagawa, S. (2205) A single intratumoral injection of a fiber-mutant adenoviral vector encoding interleukin-12 induces remarkable anti-tumor and anti-metastatic activity in mice with Meth-a fibrosarcoma. Biochem. Biophys. Res. Commun., 328: 1043-1050.
31. Green, N.K., McNeish, I.A., Doshi, R., Searle, P.F., Kerr, D.J., and Young, L.S. (2003) Immune enhancement of nitroreductase-induced cytotoxicity: studies using a bicistronic adenovirus vector. Int. J. Cancer, 104: 104-112.
32. Gridley, D.S., and Slater, J.M. (2004) Combining gene therapy and radiation against cancer. Current Gene Ther., 4: 231-248.
33. Guiducci, C., Di Carlo, E., Parenza, M., Hitt, M., Giovarelli, M., Musiani, P., and Colombo, M.P. (2004) Intralesional injection of adenovirus encoding CC chemokine ligand 16 inhibits mammary tumor growth and prevents metastatic-induced death after surgical removal of the treated primary tumor. J. Immunol., 172: 4026-4036.
34. Hallenbeck, P.L., Chang, Y.N., Hay, C., Golightly, D., Stewart, D., Lin, J., Phipps, S., and Chiang, Y.L. (1999) A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma. Hum. Gene Ther., 10: 1721-1733.
35. Haviv, Y.S., Blackwell, J.L., Kanerva, A., Nagi, P., Krasnykh, V., Dmitriev, I., Wang, M., Naito, S., Lei, X., Hemminki, A., Carey, D., and Curiel, D.T. (2002) Adenoviral gene therapy for renal cancer requires retargeting to alternative cellular receptors. Cancer Res., 62: 4273-4281.
36. Heise, C., Hermiston, T., Johnson, L., Brooks, G., Hawkins, L., and Kirn, D. (2000) An adenovirus E1A mutant that demonstrates potent and selective antitumoral efficacy. Nat. Med., 6: 1134-1139.
37. Hirschowitz, E.A., Leonard, S., Song, W., Ferris, B., Leopold, P.L., Lewis, J.J., Bowne, W.B., Wang, S., Houghton, A.N., and Crystal, R.G. (1998) Adenovirus-mediated expression of melanoma antigen gp75 as immunotherapy for metastatic melanoma. Gene Ther., 5: 975-983.
38. Holterman, L., Vogels, R., van der Vlugt, R., Sieuwerts, M., Grimbergen, J., Kaspers, J., Geelen, E., van der helm, E., Lemckert, A., Gillissen, G., Verhaagh, S., Custers, J., Zuijdgeest, D., Berkhout, B., Bakker, M., Quax, P., Goudsmith, J., and Havenga, M. (2004) Novel replication-incompetent vector derived from adenovirus type 11 (Ad11) for vaccination and gene therapy: low seroprevalence and non-cross-reactivity with Ad5. J. Virol., 78: 13207-13215.
39. Howe, J.A., Demers, G.W., Johnson, D.E., Neugebauer, S.E., Perry, S.T., Vaillancourt, M.T., and Faha, B. (2000) Evaluation of E1-mutant adenoviruses as conditionally replicating agents for cancer therapy. Mol. Ther., 2: 485-495.
40. Irving, J., Wang, Z., Powell, S., O'Sullivan, C., Mok, M., Murphy, B., Cardoza, L., Lebkowski, J.S., and Majumdar, A.S. (2004) Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity. Cancer Gene Ther., 11: 174-185.
41. Kaplan, J.M., Armentano, D., Sparer, T.E., Wynn, S.G., Peterson, P., Wadsworth, S.C., Couture, K.K., Pennington, S.E., St.George, J.A., Gooding, L.R., and Smith, A.E. (1997) Characterization of factors involved in modulating persistence of transgene expression from recombinant adenovirus in the mouse lung. Hum. Gene Ther., 8: 45-46.
42. Kaplan, J.M., Yu, Q., Piraino, S.T., Pennington, S.E., Shankara, S., Woodworth, L.A., and Roberts, B.L. (1999) Induction of antitumor immunity with dendritic cells transduced with adenovirus vector encoding endogenous tumor-associated antigens. J. Immunol., 163: 699-707.
43. Kaplan, J.M. (2004) New cancer vaccine approaches. Drugs Today, 40: 913-929.
44. Katze, M.G., He, Y., Gale, M. Jr. (2002) Viruses and interferon: a fight for supremacy. Nat. Rev. Immunol., 2: 675-687.
45. Khorana, A.A., Rosenblatt, J.D., Sahasradudhe, D.M., Evans, T., Ladrigan, M., Marquis, D., Rosell, K., Whiteside, T., Philippe, S., Acres, B., Slos, P., Suiban, P., Ross, M., and Kendra, K. (2003) A Phase I trial of immunotherapy with intratumoral adenovirus-interferon-gamma (TG1041) in patients with malignant melanoma. Cancer Gene Ther., 10: 251-259.
46. Kianmanesh, A., Hackett, N.R., Lee, J.M., Kikuchi, T., Korst, R.J., and Crystal, R.G. (2001) Intratumoral administration of low doses of an adenovirus vector encoding tumor necrosis factor alpha together with naïve dendritic cells elicits significant suppression of tumor growth without toxicity. Hum. Gene Ther., 12: 2035-2049.
47. Kikuchi, T., and Crystal, R.G. (1999) Anti-tumor immunity induced by in vivo adenovirus vector-mediated expression of CD40 ligand in tumor cells. Hum. Gene Ther., 10: 1375-1387.
48. Korst, R.J., Ailawadi, M., Lee, J.M., Lee, S., Yamada, R., Mahtabifard, A., and Crystal, R.G. (2001) Adenovirus gene transfer vectors inhibit growth of lymphatic tumor metastases independent of a therapeutic Gene Hum. Gene Ther., 12: 1639-1649.
49. Kurihara, T., Brough, D.E., Kovesdi, I., and Kufe, D.W. (2000) Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen. J. Clin. Invest., 106: 763-771.
50. Lang, F.F., Bruner, J.M., Fuller, G.N., Aldape, K., Prados, M.D., Cahng, S., Berger, M.S., Mcdermott, M.W., Kunwar, S.M., Junck, L.R., Chandler, W., Zwiebel, J.A., Kaplan, R.S., and Yung, W.K. (2003) Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. J. Clin. Oncol., 21: 2508-2518.
51. Li, G., Sham, J., Yang, J., Su, C., Xue, H., Chua, D., Sun, L., Zhang, C., Wu, M., and Qian, Q. (2005a) Potent antitumor efficacy of an E1B 55kDa-deficient adenovirus carrying murine endostatin in hepatocellular carcinoma. Int. J. Cancer., 113: 640-648.
52. Li, G., Yang, J., Nie, M., Su, C., Sun, L., Qian, Y., Fang, G., Sham, J., Wu, M., and Qian, Q. (2005b) Potent antitumoral effects of a novel gene-viral therapeutic system CNHK300-mendostatin in hepatocellular carcinoma. Chin. Med. J., 118: 179-185.
53. Liu, M., Acres, B., Balloul, J.-M., Bizouarne, N., Paul, S., Slos, P., and Squiban, P. (2004) Gene-based vaccines and immunotherapeutics. PNAS, 101: 14567-14571.
54. Liu, P., Wang, Y., Li, Y.H., Yang, C., Zhou, Y.L., Li, B., Lu, S.H., Yang, R.C., Cai, Y.L., Tobelem, G., Caen, J., and Han, Z.C. (2003) Adenovirus-mediated gene therapy with an antiangiogenic fragment of thrombospondin-1 inhibits human leukemia xenograft growth in nude mice. Leuk Res., 27: 701-708.
55. Loskog, A., Dzojic, H., Vikman, S., Ninalga, C., Essand, M., Korsgren, O., and Totterman, T.H. (2004) Adenovirus CD40 ligand gene therapy counteracts immune escape mechanisms in the tumor microenvironment. J. Immunol., 172: 7200-7205.
56. Mazzolini, G., Prieto, J., and Melero, I. (2003) Gene Therapy of cancer with interleukin-12. Curr. Pharm. Des., 9: 1981-1991.
57. McNeish, I.A., Bell, S.J., and Lemoine, N.R. (2004) Gene therapy progress and prospects: cancer gene therapy using tumor suppressor genes. Gene Ther., 11: 497-503.
58. Meng, W.S., Butterfield, L.H., Ribas, A., Dissette, V.B., Heller, J.B., Miranda, G.A., Glaspy, J.A., Mcbride, W.H., and Economou, J.S. (2001) Alpha-fetoprotein-specific tumor immunity induced by plasmid prime-adenovirus boost genetic vaccination. Cancer Res., 61: 8782-8786.
59. Miller, G., Lahrs, S., Pillarisetty, V.G., Shah, A.B., and DeMatteo, R.P. (2002) Adenovirus infection enhances dendritic cell immunostimulatory properties and induces natural killer and T-cell-mediated tumor protection. Cancer Res., 62: 5260-5266.
60. Miller, P.W., Sharma, S., Stolina, M., Butterfiled, L.H., Luo, J., Lin, Y., Dohadwala, M., Batra, R.K., Wu, L., Economou, J.S., and Dubinett, S.M. (2000) intratumoral administration of adenoviral interleukin 7 gene-modified dendritic cells augments specific antitumor immunity and achieves tumor eradication. Hum. Gene Ther., 11: 53-65.
61. Nagano, S., Yuge, K., Fukunaga, M., Terazaki, Y., Fujiwara, H., Komiya, S., and Kosai, K. (2004) Gene therapy eradicating distant disseminated micro-metastases by optimal cytokine expression in the primary lesion only: novel concepts for successful cytokine gene therapy. Int. J. Oncol., 24: 549-558.
62. Narvaiza, I., Mazzolini, G., Barajas, M., Duarte, M., Zaratiegui, M., Qian, C,, Melero, I., and Prieto, J. (2000) intratumoral coinjection of two adenoviruses, one encoding the chemokine IFN-gamma-inducible protein-10 and another encoding IL-12, results in marked antitumoral synergy. J. Immunol., 164: 3112-3122.
63. Nemunaitis, J., Swisher, S.G., Timmons, T., Connors D., Mack M., Doerksen L., Weill D., Wait J., Lawrence D.D., Kemp B.L., Fossella F., Glisson B.S., Hong W.K., Khuri F.R., Kurie J.M., Lee J.J., Lee J.S., Nguyen D.M., Nesbitt J.C., Perez-Soler R., Pisters K.M., Putnam J.B., Richli W.R., Shin D.M, Walsh G.L., Merritt J., and Roth J. (2000) Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small cell lung cancer. J. Clin. Oncol., 18: 609-622.
64. Nemunaitis, J., Cunningham, C., Tong, A.W., Post, L., Netto, G., Paulson, A.S., Rich, D., Balckburn, A., Sands, B., Gibson, B., Randlev, B., and Freeman, S. (2003) Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients. Cancer Gene Ther., 10: 341-352.
65. Okada, Y., Okada, N., Mizuguchi, H., Takahashi, K., Hayakawa, T., Mayumi, T., and Mizuno, N. (2004) Optimization of antitumor efficacy and safety of in vivo cytokine gene therapy using RGD fiber-mutant adenovirus vector for preexisting murine melanoma. Biochim. Biophys. Acta., 1670: 172-180.
66. O'Riordan, C.R., Lachapelle, A., Delgado, C., Parkes, V., Wadsworth, S.C., Smith, A.E., and Francis, G.E. (1999) PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo. Hum. Gene Ther., 10: 1349-1358.
67. Perricone, M.A., Claussen, K.A., Smith, K.A., Kaplan, J.M., Piraino, S., Shankara, S., and Roberts, B.L. (2000) Immunogene therapy for murine melanoma using recombinant adenoviral vectors expressing melanoma-associated antigens. Mol. Ther., 1: 275-284.
68. Perricone, M.A., Smih, K.A., Claussen, K.A., Plog, M.S., Hempel, D.M., Roberts, B.L., St. George, J.A., and Kaplan, J.M. (2004) Enhanced efficacy of melanoma vaccines in the absence of B lymphocytes. J. Immunother., 27: 273-281.
69. Pilder, S., Moore, M., Logan, J., and Shenk, T. (1986) The adenovirus E1B-55K transforming polypeptide modulates transport or cytoplasmic stabilization of viral and host cell mRNAs. Mol. Cell Biol., 6: 470-476.
70. Pinto, A.R., Fitzgerald, J.C., Giles-Davis, W., Gao, J.P., Wilson, J.M., and Ertl, H.C. (2003) Induction of CD8+ T cells to an HIV-1 antigen through a prime boost regimen with heterologous E1-deleted adenoviral vaccine carriers. J. Immunol., 171: 6774-6779.
71. Post, D.E., and Van Meir, E.G. (2003) A novel hypoxia-inducible factor (HIF) activated oncolytic adenovirus for cancer therapy. Oncogene, 22: 2065-2072.
72. Qiaohua, W., Xia, D., Carlsen, S., and Xiang, J. (2005) Adenovirus-mediated transgene-engineered dendritic cell vaccine of cancer. Current Gene Ther., 5: 237-247.
73. Raki, M., Kanerva, A., Ristimaki, A., Desmond, R.A., Chen, D.-T., Ranki, T., Sarkioja, M., Kangasniemi, L., and Hemminki, A. (2005) Combination of gemcitabine and Ad5/3-D24, a tropism modified conditionally replicating adenovirus, for the treatment of ovarian cancer. Gene Ther., 10: 1-8.
74. Raper, S.E., Chirmule, N., Lee, F.S., Wivwel, N.A., Bagg, A., Gao, G.P., Wilson, J.M., and Batshaw, M.L. (2003) Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol. Genet. Metab., 80: 148-158.
75. Rasmussen, H., Rsmussen, C., Lempicki, M., Durham, R., Brough, D., King, C.R., and Weichselbaum. (2002) TNFerade biologic: Preclinical toxicology of a novel adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha Gene Cancer Gene Ther., 9: 951-957.
76. Reid, T., Galanis, E., Abbruzzese, J., Sze, D., Wein, L.M., Andrews, J., Randlev, B., Heise, C., Uprichard, M., Hatfield, M., Rome, L., Rubin, J., and Kirn, D. (2002) Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl520): Phase II viral, immunologic, and clinical endpoints. Cancer Res., 62: 6070-6079.
77. Ren, W., Strube, R., Zhang, X., Chen, S.Y., and Huang, X.F. (2004) Potent tumor-specific immunity induced by an in vivo heat shock protein-suicide gene-based tumor vaccine. Cancer Res., 64: 6645-6651.
78. Ribas, A., Butterfield, L.H., Glaspy, J.A., and Economou, J.S. (2003) Current developments in cancer vaccines and cellular immunotherapy. J. Clin. Oncol., 21: 2415-2432.
79. Rivera, A.A., Davydova, J., Schierer, S., Wang, M., Krasnykh, V., Yamamoto, M., Curiel, D.T., and Nettelbeck, D.M. (2004) Combining high selectivity of replication with fiber chimerism for effective adenoviral oncolysis of CAR-negative melanoma cells. Gene Ther., 11: 1694-16702.
80. Rodriguez, R., Schuur, E.R., Lim, H.Y., Henderson, G.A., Simons, J.W., and Henderson, D.R. (1997) Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells; Cancer Res., 57: 2559-2563.
81. Rosenberg, S.A., Zhai, Y., Yang, J.C., Schartzentruber, D.J., Hwu, P., Marincola, F.M., Topalian, S.L., Restifo, N.P., Seipp, C.A., Einhorn, J.H., Roberts, B., and White, D.E. (1998) Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J. Natl. Cancer Inst., 90: 1894-1900.
82. Roth, J.A., and Grammer, S.F. (2003) Tumor suppressor gene therapy. Methods in Mol. Biol., 223: 577-597.
83. Rothmann, T., Hengstermann, A., Whitaker, N.J., Scheffner, M., and zur Hausen, H. (1998) Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells. J. Virol., 72: 9470-9478.
84. Sakai, Y., Morrison, B.J., Burke, J.D., Park, J.M., Terabe, M., Janik, J.E., Forni, G., Berzofsky, J.A., and Morris, J.C. (2004) Vaccination by genetically modified dendritic cells expressing a truncated neu oncogene prevents development of breast cancer in transgenic mice. Cancer Res., 64: 8022-8028.
85. Sangro, B., Mazzolini, G., Ruiz, J., Herraiz, M., Quiroga, J., Herrero, I., Benito, A., Larrache, J., Pueyo, J., Subtil, J.C., Olague, C., Sola, J., Sadaba, B., Lacasa, C., Melerao, I., Qian, C., and Prieto, J. 2004. Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors. J. Clin. Oncol., 22: 1389-1397.
86. Satoh, T., Irie, A., Egawa, S., and Baba, S. (2005) In situ gene therapy for prostate cancer. Curr. Gene Ther., 5: 11-119.
87. Shayakhmetov, D.M., Li, Z.-Y., Ni, S., and Lieber, A. (2005) Interference with the IL-1-signalling pathway improves the toxicity profile of systematically applied adenovirus vectors. J. Immunol., 174: 7310-7319.
88. Schumacher, L., Ribas, A., Dissette, V.B., McBride, W.H., Mukherji, B., Economou, J.S., and Butterfield, L.H. (2004) Human dendritic cell maturation by adenovirus transduction enhances tumor antigen-specific T-cell responses. J. Immunother., 27: 191-200.
89. Senzer, N., Mani, S., Rosemurgy, A., Nemunaitis, J., Cunningham, C., Guha, C., Bayol, N., Gillen, M., Chu, K., Rasmussen, C., Rasmussen, H., Kufe, D., Weichselbaum, R., and Hanna, N. (2004) TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: A Phase I study in patients with solid tumors. J. Clin. Oncol., 22: 592-601.
90. Shinoura, N., Yoshida, Y., Tsunoda, R., Ohashi, M., Zhang, W., Asai, A., Kirino, T., and Hamada, H. (1999) Highly augmented cytopathic effect of a fiber mutant E1B-defective adenovirus for gene therapy of gliomas. Cancer Res., 59: 3411-3416.
91. Shirakawa, T., Hamada, K., Zhang, Z., Okada, H., Tagawa, M., Kamidono, S., Kawabata, M., and Gotoh, A. (2004) A cox-2 promoter-based replication-selective adenoviral vector to target the cox-2-expressing human bladder cancer cells. Clin. Cancer Res., 10: 4342-4348.
92. Siemens, D.R., Elzey, B.D., Lubaroff, D.M., Bohlken, C., Jensen, R.J., Swanson, A.K., and Ratliff, T.L. (2001) Restoration of the ability to generate CTL in mice immune to adenovirus by delivery of virus in a collagen-based matrix. J. Immunol., 166: 731-735.
93. Slos, P., De Meyer, M., Leroy, P., Rousseau, C., and Acres, B. (2001) Immunotherapy of established tumors in mice by intratumoral injection of an adenovirus vector harboring the human IL-2 cDNA: induction of CD8(+) T-cell immunity and NK activity. Cancer Gene Ther., 8: 321-332.
94. Smith, R.R., Huebner, R.J., Rowe, W.P., Schatten, W.F., and Thomas, L.B. (1956) Studies on the use of viruses in the treatment of carcinoma of the cervix. Cancer, 9: 1211-1218.
95. Suzuki, K., Fueyo, J., Krasnykh, V., Reynolds, P.N., Curiel, D.T., and Alemany, R. (2001) A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency. Clin. Cancer Res., 7: 120-126.
96. Takanaka, K., Towata, S., Nakao, K., Mizuguchi, H., Hayakawa, T., Niwa, M., Ishii, N., and Nagayama, Y. (2003) Thyroid cancer immunotherapy with retroviral and adenoviral vectors expressing granulocyte macrophage colony stimulating factor and interleukin-12 in a rat model. Clin. Endocrinol., 59: 734-742.
97. Tanaka, F., Hashimoto, W., Robbins, P.D., Lotze, M.T., and Tahara, H. (2002) Therapeutic and specific antitumor immunity induced by coadministration of immature dendritic cells and adenoviral vector expressing biologically active IL-18. Gene Ther., 9: 1480-1486.
98. Tatsumi, T., Huang, J., Gooding, W.E., Gambotto, A., Robbins, P.D., Vujanovic, N.L., Alber, S.M., Watkins, S.C., Okada, H., and Storkus, W.J. (2003) Intratumoral delivery of dendritic cells engineered to secrete both interleukin (IL)-12 and IL-18 effectively treats local and distant disease in association with broadly reactive Tc1-type immunity. Cancer Res., 63: 6378-6386.
99. Tillman, B.W., Hayes, T.L., deGruijl, T.D., Douglas, J.T., and Curiel, D.T. (2000) Adenoviral vectors targeted to CD40 enhance the efficacy of dendritic cell-based vaccination against human papillomavirus 16-induced tumor cells in a murine model. Cancer Res., 60: 5456-5463.
100. Trudel, S., Trachtenberg, J., Toi, A., Sweet, J., Li, Z.H., Jewett, M., Tshilias, J., Zhuang, L.H., Hitt, M., Wan, Y., Gauldie, J., Graham, F.L., Dancey, J., and Stewart, A.K. (2003) A Phase I trial of adenovector-mediated delivery of interleukin-2 (AdIL-2) in high-risk localized prostate cancer. Cancer Gene Ther., 10: 755-763.
101. Tsukuda, K., Wiewrodt, R., Molnar-Kimber, K., Jovanovic, V.P., and Amin, K.M. (2002) An E2F-responsive replication-selective adenovirus targeted to the defective cell cycle in cancer cells: potent antitumoral efficacy but no toxicity to normal cell. Cancer Res., 62: 3438-3447.
102. Tuting, T., Steitz, J., Bruck, J., Gambotto, A., Steinbrink, K., DeLeo, A.B., Robbins, P., Knop, J., and Erik, A.H. (1999) Dendritic cell-based genetic immunization in mice with a recombinant adenovirus encoding murine TRP2 induces effective anti-melanoma immunity. J. Gene Med., 1: 400-406.
103. Vassaux, G. and Martin-Duque, P. (2004) Use of suicide genes for cancer gene therapy: study of the different approaches. Expert. Opin. Biol. Ther., 4: 519-530.
104. Wang, Z., Cook, T., Alber, S., Liu, K., Kovesdi, I., Watkins, S.K., Vodovotz, Y., Billiar, T.R., and Blumberg, D. (2004) Adenoviral gene transfer of the human inducible nitric oxide synthase gene enhances the radiation response of human colorectal cancer associated with alterations in tumor vascularity. Cancer Res., 64: 1386-1395.
105. Warnier, G., Duffour, M.-T., Uyttenhove, C., Gajewski, T.F., Lurquin, C., Haddada, H., Perricaudet, M., and Boon, T. (1996) Induction of a cytolytic T-cell response in mice with a recombinant adenovirus coding for tumor antigen P815A. Int. J. Cancer, 67: 303-310.
106. Weiping, L., Berencsi, K., Basak, S., Somasundaram, R., Ricciardi, R.P., Gonczol, E., Zaloudik, J., Linnenbach, A., Maruyama, H., Miniou, P., and Herlyn, D. (1997) Human colorectal cancer (CRC) antigen CO17-1A/GA733 encoded by adenovirus inhibits growth of established CRC cells in mice. J. Immunol., 159: 763-769.
107. White, E. (1994) Tumour biology: p53, guardian of Rb. Nature, 371: 21-22.
108. Wickham, T.J., Tzeng, E., Shears, L.L., II, Roelvink, P.W., Li, Y., Lee, G.M., Brough, D.E., Lizonova, A., and Kovesdi, I. (1997) Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins. J. Virol., 71: 8221-8229.
109. Wildner, O., Morris, J.C., Vahanian, N.N., Ford, H. Jr., Ramsey, W.J., and Blaese, R.M. (1999) Adenoviral vectors capable of replication improve the efficacy of HSVtk/GCV suicide gene therapy of cancer. Gene Ther., 6: 57-62.
110. Wiltox, A.M., Van Beusechem, V.W., Molenaar, B., Bras, H., Schaap, G.R., Alemany, R., Curiel, D.T., Pinedo, H.M., Wuisman, P.I., and Gerritsen, W.R. (2004) Conditionally replicative adenovirus with tropism expanded towards integrins inhibits osteosarcoma tumor growth in vitro and in vivo. Clin. Cancer Res., 10: 61-67.
111. Wu, X., and Levine, A.J. (1994) p53 and E2F-1 cooperate to mediate apoptosis. Proc. Natl. Acad. Sci., 91: 3602-3606.
112. Xia, D.J., Zhang, W.P., Zheng, S., Wang, J., Pan, J.P., Wang, Q., Zhang, L.H., Hamada, H., and Cao, X. (2002) Lymphotactin cotransfection enhances the therapeutic efficacy of dendritic cells genetically modified with melanoma antigen gp100. Gene Ther., 9: 592-601.
113. Yew, P.R., and Berk, A.J. (1992) Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein. Nature, 357: 82-85.
114. Zhan, J., Gao, Y., Wang, W., Shen, A., Aspelund, A., Young, M., Laquerre, S., Post, L., and Shen, Y. (2005) Tumor-specific intravenous gene delivery using oncolytic adenoviruses. Cancer Gene Ther., 12: 19-25.
115. Zhang, Z.L., Zou, W.G., Luo, C.X., Li, B.H., Wang, J.H., Sun, L.Y., Qian, Q.J., and Liu, X.Y. (2003). An armed oncolytic adenovirus system, ZD55-gene, demonstrating potent antitumoral efficacy. Cell Res., 13: 481-489.
116. Zhang, Z., Zou, W., Wang, J., Gu, J., Dang, Y., Li, B., Zhao, L., Qian, C., and Liu, X. (2005) Suppression of tumor growth by oncolytic adenovirus-mediated delivery of an antiangiogenic gene, soluble Flt-1. Mol. Ther., 11: 553-562.